Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936. https://doi.org/10.1056/NEJMoa1607303

Article  CAS  PubMed  Google Scholar 

Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638–3646. https://doi.org/10.1200/jco.2017.75.6155

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748. https://doi.org/10.1056/NEJMoa1609709

Article  CAS  PubMed  Google Scholar 

Finn RS, Aleshin A, Slamon DJ (2016) Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 18(1):17. https://doi.org/10.1186/s13058-015-0661-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spring LM, Wander SA, Andre F et al (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395(10226):817–827. https://doi.org/10.1016/s0140-6736(20)30165-3

Article  CAS  PubMed  Google Scholar 

Goel S, Bergholz JS, Zhao JJ (2022) Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer 22(6):356–372. https://doi.org/10.1038/s41568-022-00456-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fassl A, Geng Y, Sicinski P (2022) CDK4 and CDK6 kinases: from basic science to cancer therapy. Science 375(6577):eabc1495. https://doi.org/10.1126/science.abc1495

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ameratunga M, Kipps E, Okines AFC et al (2019) To cycle or fight-CDK4/6 inhibitors at the crossroads of anticancer immunity. Clin Cancer Res 25(1):21–28. https://doi.org/10.1158/1078-0432.Ccr-18-1999

Article  CAS  PubMed  Google Scholar 

Scirocchi F, Scagnoli S, Botticelli A et al (2022) Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(-) metastatic breast cancer: relief from immunosuppression is associated with clinical response. EBioMedicine 79:104010. https://doi.org/10.1016/j.ebiom.2022.104010

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pandey P, Khan F, Upadhyay TK et al (2023) Deciphering the immunomodulatory role of cyclin-dependent kinase 4/6 inhibitors in the tumor microenvironment. Int J Mol Sci 24(3):2236. https://doi.org/10.3390/ijms24032236

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujimoto Y, Ozawa H, Higuchi T et al (2019) Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. Mol Clin Oncol 10(2):275–284. https://doi.org/10.3892/mco.2018.1783

Article  CAS  PubMed  Google Scholar 

Zahorec R (2021) Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 122(7):474–488. https://doi.org/10.4149/bll_2021_078

Article  CAS  PubMed  Google Scholar 

Araki K, Ito Y, Fukada I et al (2018) Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer 18(1):982. https://doi.org/10.1186/s12885-018-4888-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyoshi Y, Yoshimura Y, Saito K et al (2020) High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician’s choice-in the EMBRACE study. Breast cancer (Tokyo, Japan) 27(4):706–715. https://doi.org/10.1007/s12282-020-01067-2

Article  PubMed  Google Scholar 

Kashiwagi S, Asano Y, Goto W et al (2020) Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer. Anticancer Res 40(6):3345–3354. https://doi.org/10.21873/anticanres.14317

Article  CAS  PubMed  Google Scholar 

Miyagawa Y, Yanai A, Yanagawa T et al (2020) Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. Oncotarget 11(1):86–98. https://doi.org/10.18632/oncotarget.27423

Article  PubMed  PubMed Central  Google Scholar 

Sata A, Fukui R, Miyagawa Y et al (2020) C-reactive protein and absolute lymphocyte count can predict overall survival of patients treated with eribulin. Anticancer Res 40(7):4147–4156. https://doi.org/10.21873/anticanres.14414

Article  CAS  PubMed  Google Scholar 

Takahashi M, Inoue K, Mukai H et al (2021) Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan. Breast cancer (Tokyo, Japan) 28(4):945–955. https://doi.org/10.1007/s12282-021-01232-1

Article  PubMed  Google Scholar 

Goto W, Kashiwagi S, Takada K et al (2022) Utility of follow-up with absolute lymphocyte count in patients undergoing eribulin treatment for early detection of progressive advanced or metastatic breast cancer. Anticancer Res 42(2):939–946. https://doi.org/10.21873/anticanres.15553

Article  CAS  PubMed  Google Scholar 

Kanaoka H, Nagahashi M, Atake Y et al (2022) Absolute lymphocyte count is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors. Anticancer Res 42(10):4867–4878. https://doi.org/10.21873/anticanres.15992

Article  CAS  PubMed  Google Scholar 

Nakamoto S, Shien T, Iwamoto T et al (2024) Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer. Sci Rep 14(1):9869. https://doi.org/10.1038/s41598-024-60101-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burstein HJ, Somerfield MR, Barton DL et al (2021) Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol 39(35):3959–3977. https://doi.org/10.1200/jco.21.01392

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E et al (2024) 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast (Edinburgh, Scotland) 76:103756. https://doi.org/10.1016/j.breast.2024.103756

Article  PubMed  Google Scholar 

Im SA, Gennari A, Park YH et al (2023) Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO open 8(3):101541. https://doi.org/10.1016/j.esmoop.2023.101541

Article  PubMed  PubMed Central